Clinical perspectives on platinum resistance

Drugs

Volumn 59, Issue SUPPL. 4, 2000, Pages 9-17

  Giaccone, Giuseppe ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; AMPHOTERICIN B; APHIDICOLIN; BLEOMYCIN; BUTHIONINE SULFOXIMINE; CARBOPLATIN; CISPLATIN; CYCLOSPORIN; CYTARABINE; DIMESNA; DIPYRIDAMOLE; DNA; DNA POLYMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; FLUOROURACIL; GEMCITABINE; GLUTATHIONE; HYDROXYUREA; NOVOBIOCIN; OXALIPLATIN; PACLITAXEL; SEROTONIN ANTAGONIST; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER COMBINATION CHEMOTHERAPY; DNA REPAIR; DRUG FORMULATION; DRUG POTENCY; DRUG TRANSPORT; GLUTATHIONE METABOLISM; HEAD CANCER; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; NECK CANCER; NEPHROTOXICITY; NEUROTOXICITY; OVARY CANCER; REVIEW; TESTIS CANCER; TUMOR SUPPRESSOR GENE; VOMITING;

EID: 0034117603     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059004-00002     Document Type: Review

References (56)

1. Kelland LR. Preclinical perspectives on platinum resistance. Drugs 2000; 59 Suppl. 4: 1-8
2. Judson I, Kelland LR. New developments and approaches in the platinum arena. Drugs 2000; 59 Suppl. 4: 29-36
3. Jassem J. Chemotherapy of advanced non-small cell lung cancer. Ann Oncol 1999; 10: S77-82
4. Johnson DH. Management of small cell lung cancer. Current state of the art. Chest 1999; 116: S525-30
5. Zöchbauer-Müller S, Pirker R, Huber H. Treatment of small cell lung cancer patients. Ann Oncol 1999; 10: S83-91
6. McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998; 25: 340-8
7. Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999; 25: 199-206
8. Thigpen T. Second-line therapy for ovarian carcinoma: general concepts. American Society of Clinical Oncology 1999 Educational Book; Atlanta, 1999
9. Chen G, Hutter KJ, Zeller WJ. Positive correlation between cellular glutathione and acquired cisplatin resistance in human ovarian cancer cells. Cell Biol Toxicol 1995; 11: 273-81
10. Muggia FM, Los G. Platinum resistance: laboratory findings and clinical implications. Stem Cells 1993: 11; 182-93
11. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992; 10 (4): 513-4
12. Giaccone G. Identification of new drugs in pretreated patients with small cell lung cancer. Eur J Cancer Clin Oncol 1989; 25: 411-3
13. Giaccone G, Donadio M, Bonardi G, et al. Teniposide in the treatment of small cell lung cancer: the influence of prior chemotherapy. J Clin Oncol 1988; 6: 1264-70
14. Giaccone G, Dalesio O, McVie GJ, et al. Maintenance chemotherapy in small cell lung cancer: long term results of a randomized trial. J Clin Oncol 1993; 11: 1230-40
15. Johnson DH, Greco FA, Strupp J, et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase II trial. J Clin Oncol 1990; 8: 1613-7
16. Godwin AK, Meister A, O'Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070-4
17. O'Dwyer PJ, Johnson SW, Hamilton TC. Cisplatin and its analogues. In: DeVita VT, Hellman S, Rosemberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott Publishers, 1997: 418-32
18. Izquierdo MA, Scheffer GL, Flens MJ, et al. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996; 19: 191-7
19. Izquierdo MA, van der Zee AG, Vermorken JB, et al. Drug resistance-associated marker LRP for prediction of response to chemotherapy and prognoses in advanced ovarian carcinoma. J Natl Cancer Inst 1995; 87: 1230-7
20. Uchiumi T, Hinoshita E, Haga S, et al. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatin-resistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 1998; 252: 103-10
21. Britten RA, Green JA, Warenius HM. Cellular glutathione (GSH) and glutathione-S-transferases (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents, Int J Radiat Oncol Biol Phys 1992; 64: 527-31
22. Ali-Osmon F, Berger MS, Rairkar A, et al. Enhanced repair of a cisplatin-damaged reporter chloramphenicol-O-acetyl-transferase gene and altered activities of DNA polymerases alpha and beta, and DNA ligase in cells of a human malignant glioma following in vivo cisplatin therapy. J Cell Biochem 1994; 54: 11-9
23. Reed E, Ozols RF, Tarone R, et al. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci USA 1987; 84; 5024-8
24. Ma J, Verweij J, Planting ASTL, et al. Current sample handling methods for measurement of platinum-DNA adducts in leukocytes in man lead to discrepant results in DNA adduct levels and DNA repair. Br J Cancer 1995; 71: 512-7
25. Schellens JHM, Ma J, Planting ASTL, et al. Relationship between the exposure to cisplatin, DNA adduct formation in leukocytes, and tumor response in patients with solid tumors. Br J Cancer 1996; 73: 1569-75
26. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-44
27. Dabholkar M, Viommet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94: 703-8
28. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-16
29. Dabholkar M, Berger MS, Vionnet JA, et al. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995; 55: 1261-6
30. Crul M, Schellens JHM, Beijnen JH, et al. Cisplatin resistance and DNA repair. Cancer Treat Rev 1997; 23: 341-66
31. Aebi S, Kurdi-Haidar B, Gordon R, et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 1996; 56: 3087-90
32. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4: 1-6
33. Brown R, Hirst GL, Gallagher WM, et al. hMLHI expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents. Oncogene 1997; 15: 45-52
34. Ferreira CG, Tolis C, Giaccone G. P53 and chemosensitivity. Ann Oncol 1999; 10: 1011-21
35. Herod JJ, Eliopoulos AG, Warwick J, et al. The prognostic significance of Bel-2 and p53 expression in ovarian carcinoma. Cancer Res 1995; 55: 1649-54
36. Kaye SB, Paul J, Cassidy J, et al. Randomized study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 1992; 340: 329-33
37. Kaye SB, Paul J, Cassidy J, et al. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group. J Clin Oncol 1996; 14 (7): 2113-9
38. Nichols CR, Williams SD, Loehrer PJ, et al. Cisplatin dose-intensity in testicular cancer treatment: analysis of a randomized clinical trial. In: Howell SB, editor. Platinum and other metal coordination compounds in cancer chemotherapy. New York: Plenum Press, 1991: 409-20
39. Wandt H, Birkmann J, Denzel T, et al. Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 1999; 23: 763-70
40. Hirai T, Korogi Y, Hamatake S, et al. Stages III and IV squamous cell carcinoma of the mouth: three-year experience with superselective intraarterial chemotherapy using cisplatin prior to definitive treatment. Cardiovasc Intervent Radiol 1999; 22: 201-5
41. Shami J, Bertram J, Russell C, et al. Noninvasive monitoring of drug biodistribution: studies with intra-arterial Pt-195m-cisplatin in humans. Cancer Res 1989; 49: 1877-81
42. Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5
43. Gabizon A. Tailoring liposomes for cancer drug delivery: from the bench to the clinic. Ann Biol Clin (Paris) 1993; 51: 811-3
44. Newman MS, Colbern GT, Working PK, et al. Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice. Cancer Chemother Pharmacol 1999; 43: 1-7
45. Kashani-Sabet M, Wang W, Scanlon KJ. Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 1990; 265: 11285-8
46. Manetta A, Blessing JA, Hurteau JA. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. Gynecol Oncol 1998; 68 (1): 45-6
47. Lertratanangkoon K, Savaraj N, Scimeca JM, et al. Glutathione depletion-induced thymidylate insufficiency for DNA repair synthesis. Biochem Biophys Res Commun 1997; 19: 470-5
48. Lai G-M, Ozols RF, Young RC, et al. Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. Biochem Pharmacol 1989; 37: 4597-600
49. Calvert P, Yao KS, Hamilton TC, et al. Clinical studies of reversal of drug resistance based on glutathione. Chem Biol Interact 1998 Apr 24: 111-2, 213-24
50. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59 Suppl. 4: 19-27
51. Howell SB, Pfeifle CE, Wung WE, et al. Intraperitoneal cisdiamminedichloroplatinum with synthetic thiosulfate protection. Cancer Res 1983; 43: 1426-31
52. Lebwohl D, Canetta R. Clinial development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998; 34: 1522-34
53. Perez RP. Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 1998; 34: 1535-42
54. Crino L, Scagliotti GV, Marangolo M, et al. Cisplatingemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1997; 15: 297-303
55. Hancock MC, Langton BC, Chan T, et al. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatin against human breast and ovarian tumor cell lines. Cancer Res 1991; 51: 4575-80
56. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998; 16: 2659-71